We aimed to explore the efficacy and safety of etoposide capsule combined with cisplatin or carboplatin in the treatment of elderly patients with small cell lung cancer （SCLC）. Methods： From October 2011 to Novembe...We aimed to explore the efficacy and safety of etoposide capsule combined with cisplatin or carboplatin in the treatment of elderly patients with small cell lung cancer （SCLC）. Methods： From October 2011 to November 2013, 32 elderly patients （71-79 years old） with histopathologically confirmed SCLC in General Hospital of Shenyang Military Region （China） were enrolled in the research. The patients were administrated with lastet capsule 150-175 mg, dl-5, combined with cisplatin 20 mg/m^2 dl-3 or carbopiatin AUC = 5, applied over 2 days. Twenty-one days were 1 treatment cycle. Results：After treatments, 2 cases acquired complete response （CR）, 19 cases acquired partial response （PR）, 8 cases acquired stable disease （SD）, and 3 cases had progression of disease （PD）. The objective response rate was 65.6% （21/32）, disease control rate was 90.6% （29/32）. The median time of progression-free survival （PFS） was 6.9 months, the median survival time was 14.0 months, and 1 year survival rate was 62.4%. The main adverse reactions of 1/11 leukopenia and gastrointestinal reaction were observed. Conclusion： Etoposide capsule combined with cisplatin or carboplatin therapy have curative effect and good tolerance in elderly patients with SCLC.展开更多
<div style="text-align:justify;"> <span style="font-family:Verdana;">Endometrial neuroendocrine tumors are rare, accounting less than 1% of endometrial cancers. They include small cell ...<div style="text-align:justify;"> <span style="font-family:Verdana;">Endometrial neuroendocrine tumors are rare, accounting less than 1% of endometrial cancers. They include small cell neuroendocrine carcinoma (NEC) and large cell NEC and usually occur in postmenopausal patients. Although common symptoms include postmenopausal bleeding, most patients are diagnosed at an advanced stage. We report an extremely rare case of small cell NEC developed in the endometrium of a 75-year-old Japanese woman. This case was initially suspected based on the findings of endometrial cytology: a number of small round malignant cells were present on the endometrial smear specimens. The immunocytochemical and immunohistochemical examinations revealed diffusely cytoplasmic positive reaction of neuron specific enolase (NSE) and partially membranous positive reaction of CD56 in the small cancer cells. They showed PAX-8-positive reaction, but did not express microsatellite instability high. Electron micrography showed several dense-core secretory granules in the cytoplasm of cancer cells. Despite multiple lung metastases, the patient underwent a hysterectomy and salpingo-oophorectomy in order to control excessive genital bleeding. She received six courses of adjuvant chemotherapy based on etoposide and cisplatin, and survived healthy eight months after the first visit without any viability of lung metastases.</span> </div>展开更多
基金Supported by grants from the Sub-Topics of Major Drug Discovery Platform in the Twelfth-Five Year Research Program of China(No.2012ZX09303016-002)China Postdoctoral Science Foundation(No.2012M512119)
文摘We aimed to explore the efficacy and safety of etoposide capsule combined with cisplatin or carboplatin in the treatment of elderly patients with small cell lung cancer （SCLC）. Methods： From October 2011 to November 2013, 32 elderly patients （71-79 years old） with histopathologically confirmed SCLC in General Hospital of Shenyang Military Region （China） were enrolled in the research. The patients were administrated with lastet capsule 150-175 mg, dl-5, combined with cisplatin 20 mg/m^2 dl-3 or carbopiatin AUC = 5, applied over 2 days. Twenty-one days were 1 treatment cycle. Results：After treatments, 2 cases acquired complete response （CR）, 19 cases acquired partial response （PR）, 8 cases acquired stable disease （SD）, and 3 cases had progression of disease （PD）. The objective response rate was 65.6% （21/32）, disease control rate was 90.6% （29/32）. The median time of progression-free survival （PFS） was 6.9 months, the median survival time was 14.0 months, and 1 year survival rate was 62.4%. The main adverse reactions of 1/11 leukopenia and gastrointestinal reaction were observed. Conclusion： Etoposide capsule combined with cisplatin or carboplatin therapy have curative effect and good tolerance in elderly patients with SCLC.
文摘<div style="text-align:justify;"> <span style="font-family:Verdana;">Endometrial neuroendocrine tumors are rare, accounting less than 1% of endometrial cancers. They include small cell neuroendocrine carcinoma (NEC) and large cell NEC and usually occur in postmenopausal patients. Although common symptoms include postmenopausal bleeding, most patients are diagnosed at an advanced stage. We report an extremely rare case of small cell NEC developed in the endometrium of a 75-year-old Japanese woman. This case was initially suspected based on the findings of endometrial cytology: a number of small round malignant cells were present on the endometrial smear specimens. The immunocytochemical and immunohistochemical examinations revealed diffusely cytoplasmic positive reaction of neuron specific enolase (NSE) and partially membranous positive reaction of CD56 in the small cancer cells. They showed PAX-8-positive reaction, but did not express microsatellite instability high. Electron micrography showed several dense-core secretory granules in the cytoplasm of cancer cells. Despite multiple lung metastases, the patient underwent a hysterectomy and salpingo-oophorectomy in order to control excessive genital bleeding. She received six courses of adjuvant chemotherapy based on etoposide and cisplatin, and survived healthy eight months after the first visit without any viability of lung metastases.</span> </div>
